Ceftriaxone

also known as Ceftriaxone sodium · Rocephin · Ceftriaxon · CTX · Anerning particle · Cefraden · Ceftriaxona · Ceftriaxone (as sodium) · +15 more

Other / unclassified

Developed for: pneumonia · infectious disease with sepsis · acute pyelonephritis · appendicitis · bacterial infectious disease · gonorrhea · HIV infectious disease · protein-energy malnutrition
+59 more
· cirrhosis of liver · infective endocarditis · puerperal infection · urinary tract infection · articular cartilage disorder · aspiration pneumonia · aspiration pneumonitis · bacterial infectious disease with sepsis · bacterial meningitis · bacterial pneumonia · bacterial urinary tract infection · bacterial vaginosis · bipolar disorder · cellulitis · cervical incompetence · cholangitis · COVID-19 · critical illness polyneuropathy · diarrheal disease · endocarditis · escherichia coli infection · esophageal varices with bleeding · hidradenitis suppurativa · infectious disease · infectious disorder of the nervous system · infectious peritonitis · intestinal infectious disease · liver disorder · Lyme disease · meningitis · neurosyphilis · Parkinson disease · post-treatment Lyme disease syndrome · preterm premature rupture of the membranes · pulmonary non-tuberculous mycobacterial infection · respiratory tract infectious disorder · salmonellosis · schizoaffective disorder · schizophrenia · streptococcal pneumonia · typhoid fever · ulcerative colitis · abscess · amyotrophic lateral sclerosis · bacterial arthritis · bipolar depression · cholecystitis · diverticulitis · endometritis · gram-negative bacterial infections · infective arthritis · liver abscess (disease) · nosocomial infection · osteomyelitis · peritonitis · pyelonephritis · shigellosis · staphylococcal infection · syphilis
Investigated by: Andalusian Public Foundation for Health Research in Seville · University of Oxford · Makerere University · Merck Sharp & Dohme LLC · Assistance Publique Hopitaux De Marseille · Hoffmann-La Roche
+138 more
· KEMRI-Wellcome Trust Collaborative Research Program · London School of Hygiene and Tropical Medicine · Ministry of Health, France · National Institute of Allergy and Infectious Diseases (NIAID) · Pfizer · Spanish Network for Research in Infectious Diseases · Theriva Biologics, Inc. · University College, London · Xiangbei Welman Pharmaceutical Co., Ltd · Academic Medical Center - University of Amsterdam · Aga Khan University · Ahmad Zia · Ain Shams Maternity Hospital · Albert Schweitzer Hospital · American Association for the Study of Liver Diseases · Amsterdam UMC, location VUmc · Assistance Publique - Hôpitaux de Paris · Assiut University · Association Pour La Promotion A Tours De La Reanimation Medicale · Austin V Stone · Australian and New Zealand Intensive Care Research Centre · Baxter Healthcare Corporation · Berry Consultants · Beth Israel Deaconess Medical Center · Biopharma (Orofino Pharmaceuticals Group) · BrainX Corporation · CH SOISSONS · Centre Hospitalier Roubaix · Centre Hospitalier Universitaire de Besancon · Centre Hospitalier Universitaire de Caen · Centre Hospitalier Universitaire de Nice · Centre Hospitalier Universitaire, Amiens · Centre Hospitalier de Beauvais · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal · Centre for Clinical Research, Kenya Medical Research Institute · Centre for Microbiology Research, Kenya Medical Research Institute · Centre for Research in Therapeutic Sciences, Strathmore University, Nairobi Kenya · Chang Gung Memorial Hospital · China Academy of Chinese Medical Sciences · Columbia Clinical Trials Network for Lyme and Other Tick-Borne Diseases · David J. Gagnon · Department for International Development, United Kingdom · E-DA Hospital · Erasmus Medical Center · Far Eastern Memorial Hospital · Fondo de Investigacion Sanitaria · French Society for Intensive Care · GlaxoSmithKline · Global Coalition for Adaptive Research · HaEmek Medical Center, Israel · Hackensack Meridian Health · Haiphong University of Medicine and Pharmacy · Halozyme Therapeutics · Hospital Mutua de Terrassa · Hospital Universitario Principe de Asturias · Hôpital Les Bateliers, CHU de Lille · IL Sogno di Stefano · Imperial College London · Innoviva Specialty Therapeutics · Institut Pasteur · Intensive Care National Audit & Research Centre · Johns Hopkins All Children's Hospital · Kamuzu University of Health Sciences · Kenya Medical Research Institute · Kenya Ministry of Health · Korea University · MEDSI Clinical Hospital 1, ICU · Maasstad Hospital · MaineHealth · Manimarane Arjunan, MD,DM (Cardiology) · Massachusetts General Hospital · Mbarara University of Science and Technology · Medical College of Wisconsin · Medical Research Council · all 144 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	ROCEPHIN KIT	—	1984-12-21	fda.gov ↗

Trials 86 · started per year

today

US approved 1984

1984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial
Phase 0	NCT04977882	Oct 2020 → Aug 2022	colon carcinoma	University of Rome Tor Vergata	Completed	No outcome recorded
Phase 13 trials
Phase 1	NCT03895567	Dec 2026	—	University of Oxford	Suspended	No outcome recorded
Phase 1	NCT05724628	Oct → Nov 2023	appendicitis	University of Texas Southwestern Medical Center	Withdrawn	No outcome recorded
Phase 1	NCT00493220	Jun → Sep 2007	—	Baxter Healthcare Corporation	Completed	No outcome recorded
Phase 1/24 trials
Phase 1/2	NCT06785402	May 2026	post-treatment Lyme disease syndrome	Hackensack Meridian Health	Withdrawn	No outcome recorded
Phase 1/2	NCT02473640	Jun 2015 → Apr 2016	—	Theriva Biologics, Inc.	Completed	No outcome recorded
Phase 1/2	NCT02419001	Mar → Sep 2015	—	Theriva Biologics, Inc.	Completed	No outcome recorded
Phase 1/2	NCT00591318	Oct 2007 → Mar 2011	schizoaffective disorder, schizophrenia	Research Foundation for Mental Hygiene, Inc.	Terminated	No outcome recorded
Phase 214 trials
Phase 2	NCT07485010	Apr 2027 → Apr 2031 expected	pulmonary non-tuberculous mycobacterial infection	The University of Queensland	Not yet recruiting	No outcome recorded
Phase 2	NCT06406114	May 2025 → Jul 2028 expected	anaphylaxis, drug allergy, drug pseudoallergy	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 2	NCT05470517	Jan 2023 → Feb 2024	appendicitis	Johns Hopkins All Children's Hospital	Completed	No outcome recorded
Phase 2	NCT05375240	Jun 2022 → Jun 2024	ischemic stroke	Tianjin Medical University General Hospital	Unknown	No outcome recorded
Phase 2	NCT05149287	Dec 2021 → Apr 2022	articular cartilage disorder	Austin V Stone	Terminated	No outcome recorded
Phase 2	NCT04999592	Aug 2021 → Mar 2024	cardiac arrest, pneumonia	David J. Gagnon	Terminated	No outcome recorded
Phase 2	NCT05216744	Jul 2021 → Feb 2022	chlamydia trachomatis infectious disease, gonorrhea	Haiphong University of Medicine and Pharmacy	Completed	No outcome recorded
Phase 2	NCT03794765	Apr 2019 → Mar 2020	ulcerative colitis	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
Phase 2	NCT03413384	Feb 2019 → Jul 2025 overdue	Parkinson disease	BrainX Corporation	Active not recruiting	No outcome recorded
Phase 2	NCT03681431	Apr 2018 → Apr 2019	infective endocarditis	Andalusian Public Foundation for Health Research in Seville	Completed	No outcome recorded
Phase 2	NCT02746276	Apr → Sep 2016	protein-energy malnutrition	University of Oxford	Unknown	No outcome recorded
Phase 2	NCT00512616	Aug 2007 → Sep 2009	bipolar disorder	National Institute of Mental Health (NIMH)	Withdrawn	No outcome recorded
Phase 2	NCT00451386	Jan 2002 → Dec 2003	bacterial pneumonia, urinary tract infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 2	NCT00037479	Dec 1999 → ?	Lyme disease	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	No outcome recorded

Phase 2/33 trials
Phase 2/3	NCT06527989	Sep 2024 → Sep 2025 overdue	—	Assiut University	Not yet recruiting	No outcome recorded
Phase 2/3	NCT05051163	Jun 2021 → Jun 2024	HIV infectious disease, protein-energy malnutrition	Makerere University	Unknown	No outcome recorded
Phase 2/3	NCT02561442	Oct → Dec 2015	—	scPharmaceuticals, Inc.	Completed	No outcome recorded
Phase 318 trials
Phase 3	NCT06572761	Sep 2026 → May 2030 expected	cervical incompetence	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 3	NCT07710118	Jul 2026 → Dec 2028 expected	gonorrhea	National Taiwan University Hospital	Recruiting	No outcome recorded
Phase 3	NCT05821478	May 2025 → Feb 2027 expected	hidradenitis suppurativa	Institut Pasteur	Recruiting	No outcome recorded
Phase 3	NCT05654896	Nov 2022 → Nov 2023	—	Nadeem Iqbal	Unknown	No outcome recorded
Phase 3	NCT04041791	Aug 2019 → Apr 2024	pneumonia	University of Oxford	Completed	No outcome recorded
Phase 3	NCT03174236	Sep 2017 → Jan 2020	poisoning, protein-energy malnutrition	University of Oxford	Unknown	No outcome recorded
Phase 3	NCT02389036	May 2017 → Apr 2023	critical illness polyneuropathy, infectious disease with sepsis	The George Institute	Completed	No outcome recorded
Phase 3	NCT02795949	Oct 2016 → Jan 2020	bacterial infectious disease	Andalusian Public Foundation for Health Research in Seville	Completed	No outcome recorded
Phase 3	NCT02735707	Apr 2016 → Feb 2026 overdue	pneumonia	UMC Utrecht	Recruiting	No outcome recorded
Phase 3	NCT02265406	Oct 2015 → Jul 2020	—	Poitiers University Hospital	Completed	No outcome recorded
Phase 3	NCT02142751	Jul 2014 → Dec 2018	escherichia coli infection	Andalusian Public Foundation for Health Research in Seville	Completed	No outcome recorded
Phase 3	NCT03477422	Jan 2014 → May 2017	acute pyelonephritis	Venus Remedies Limited	Completed	No outcome recorded
Phase 3	NCT02177994	Sep 2013 → Aug 2014	puerperal infection	Ain Shams Maternity Hospital	Completed	No outcome recorded
Phase 3	NCT01473836	Nov 2011 → Oct 2012	infectious peritonitis	Pfizer	Completed	No outcome recorded
Phase 3	NCT00372541	Sep 2006 → Mar 2007	pneumonia	Makerere University	Completed	No outcome recorded
Phase 3	NCT00189384	Nov 2003 → Dec 2005	bacterial infectious disease with sepsis	Aga Khan University	Unknown	No outcome recorded
Phase 3	NCT00481702	Dec 2001 → Jun 2003	intestinal infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00161330	Jun 2000 → Jul 2005	urinary tract infection	University of Padova	Terminated	No outcome recorded

Phase 431 trials
Phase 4	NCT07484633	Apr 2026 → Apr 2028 expected	infectious disease with sepsis	Semmelweis University	Not yet recruiting	No outcome recorded
Phase 4	NCT06766461	Jan 2025 → Dec 2026 expected	infectious disease with sepsis	Erasmus Medical Center	Recruiting	No outcome recorded
Phase 4	NCT06423898	Oct 2024 → Jul 2027 expected	infective endocarditis	Andalusian Public Foundation for Health Research in Seville	Recruiting	No outcome recorded
Phase 4	NCT06494072	Aug 2024 → May 2028 expected	—	Medical College of Wisconsin	Recruiting	No outcome recorded
Phase 4	NCT06349122	Aug 2024 → Mar 2027 expected	bacterial vaginosis	Assistance Publique Hopitaux De Marseille	Not yet recruiting	No outcome recorded
Phase 4	NCT06396078	Jul 2024 → Dec 2026 expected	preterm premature rupture of the membranes	Ohio State University	Recruiting	No outcome recorded
Phase 4	NCT06220929	Jan → Dec 2024	infectious disease with sepsis, liver disorder	Sichuan Provincial People's Hospital	Unknown	No outcome recorded
Phase 4	NCT05156437	Mar 2022 → Oct 2024	endocarditis	West Virginia University	Terminated	No outcome recorded
Phase 4	NCT05079620	Nov 2021 → Apr 2024	aspiration pneumonia, aspiration pneumonitis	UConn Health	Terminated	No outcome recorded
Phase 4	NCT04975945	Aug → Dec 2021	—	The Grant Medical College & Sir J.J. Group of Hospitals	Withdrawn	No outcome recorded
Phase 4	NCT04218695	Aug 2020 → May 2021	cirrhosis of liver	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
Phase 4	NCT04056806	Aug 2019 → Jun 2022	esophageal varices with bleeding	E-DA Hospital	Unknown	No outcome recorded
Phase 4	NCT03675178	Sep 2018 → Jun 2019	pneumonia	China Academy of Chinese Medical Sciences	Unknown	No outcome recorded
Phase 4	NCT03012360	Feb 2018 → Jul 2024	—	University Hospital, Lille	Terminated	No outcome recorded
Phase 4	NCT03179384	Jun 2017 → Feb 2019	acute pyelonephritis	Centre Hospitalier Universitaire de Nice	Completed	No outcome recorded
Phase 4	NCT02736682	Sep 2015 → Feb 2016	puerperal infection	Makerere University	Completed	No outcome recorded
Phase 4	NCT04202068	Jul 2015 → May 2016	gonorrhea	Xiangbei Welman Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 4	NCT04066621	Apr 2015 → Jun 2016	bacterial urinary tract infection, respiratory tract infectious disorder	Xiangbei Welman Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 4	NCT02224040	Aug 2013 → Dec 2014	typhoid fever	Sheba Medical Center	Unknown	No outcome recorded
Phase 4	NCT01745679	Dec 2012 → Dec 2015	infectious disorder of the nervous system, meningitis	Nantes University Hospital	Completed	No outcome recorded
Phase 4	NCT01390623	Jul 2011 → Jul 2013	acute pyelonephritis	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 4	NCT01278017	Aug 2010 → Jun 2011	diarrheal disease	Chang Gung Memorial Hospital	Unknown	No outcome recorded
Phase 4	NCT01247909	Apr 2010 → Feb 2015	bacterial meningitis	Kamuzu University of Health Sciences	Completed	No outcome recorded
Phase 4	NCT01678365	Jul 2008 → Oct 2009	appendicitis	HaEmek Medical Center, Israel	Completed	No outcome recorded
Phase 4	NCT01265173	Apr 2007 → Jun 2018	cirrhosis of liver	Korea University	Completed	No outcome recorded
Phase 4	NCT00449800	Jul 2006 → Mar 2007	infectious disease with sepsis	Association Pour La Promotion A Tours De La Reanimation Medicale	Unknown	No outcome recorded
Phase 4	NCT00429975	Aug 2004 → Sep 2005	streptococcal pneumonia	Hospital Mutua de Terrassa	Terminated	No outcome recorded
Phase 4	NCT00157898	Jan → Aug 2004	—	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 4	NCT00035347	Jan 2001 → Jun 2002	pneumonia	Pfizer	Completed	No outcome recorded
Phase 4	NCT00374959	Oct 2000 → Oct 2003	pneumonia	Hospital Universitario Principe de Asturias	Completed	No outcome recorded
Phase 4	NCT01559753	Jan 1998 → Sep 2002	—	Centre Hospitalier Universitaire de Besancon	Completed	No outcome recorded

Phase not applicable12 trials
—	NCT07030673	Feb 2025 → Mar 2027 expected	viral infectious disease	Centre Hospitalier Universitaire, Amiens	Recruiting	No outcome recorded
—	NCT06532409	Oct 2024 → Sep 2025 overdue	pneumonia	RESnTEC, Institute of Research	Not yet recruiting	No outcome recorded
—	NCT07308457	Sep 2024 → Jun 2027 expected	infectious disease	Pomeranian Medical University Szczecin	Recruiting	No outcome recorded
—	NCT05750966	Jul 2023 → Apr 2026	cholangitis	Academic Medical Center - University of Amsterdam	Completed	No outcome recorded
—	NCT04839653	May 2021 → Apr 2022	acute respiratory distress syndrome, bacterial infectious disease, infectious disease with sepsis, pneumonia	MEDSI Clinical Hospital 1, ICU	Unknown	No outcome recorded
—	NCT04935515	Apr → May 2021	COVID-19	Manimarane Arjunan, MD,DM (Cardiology)	Completed	No outcome recorded
—	NCT03518463	Jun → Jul 2017	pregnancy disorder	Mbarara University of Science and Technology	Completed	No outcome recorded
—	NCT02996656	Dec 2016 → Dec 2026 expected	bacterial infectious disease	University of Montreal	Recruiting	No outcome recorded
—	NCT02334124	Jan 2015 → Jun 2017	cellulitis	Murdoch Childrens Research Institute	Completed	No outcome recorded
—	NCT01988428	Jun 2014 → Jun 2017	infectious disease with sepsis	Amsterdam UMC, location VUmc	Completed	No outcome recorded
—	NCT00000648	? → Feb 1996	HIV infectious disease, neurosyphilis	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
—	NCT00002052	—	HIV infectious disease, salmonellosis	University of Southern California	Completed	No outcome recorded

Also used as a comparator or background therapy in 104 trials

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT06611111 Comparator	Feb 2025 → Dec 2026 expected	post-treatment Lyme disease syndrome	State University of New York - Upstate Medical University	Recruiting	No outcome recorded
Phase 0	NCT05761405 Comparator	Jan 2024 → Oct 2025	urinary tract infection	Centre Hospitalier Universitaire Vaudois	Unknown	No outcome recorded
Phase 0	NCT05849090 Comparator	Mar 2023 → Dec 2024	infectious disease	University of Utah	Completed	No outcome recorded
Phase 0	NCT02099240 Comparator	Mar 2014 → Nov 2018	osteomyelitis	University of Louisville	Terminated	No outcome recorded
Phase 14 trials
Phase 1	NCT06616168 Background	Sep 2023 → Aug 2026 overdue	bacterial vaginosis	Danylo Halytsky Lviv National Medical University	Active not recruiting	No outcome recorded
Phase 1	NCT03840811 Background	Apr 2017 → Nov 2019	gonorrhea	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT04870138 Background	Mar 2013 → Apr 2015	gonorrhea	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 1	NCT00004216 Background	Aug 1999 → Jan 2008	cancer of unknown primary site	Vion Pharmaceuticals	Completed	No outcome recorded
Phase 1/21 trial
Phase 1/2	NCT04461925 Background	May 2020 → May 2021	pneumonia	Institute of Cell Therapy	Unknown	No outcome recorded
Phase 213 trials
Phase 2	NCT07318584 Comparator	Mar 2026 → Feb 2028 expected	escherichia coli discitis	Oregon Health and Science University	Not yet recruiting	No outcome recorded
Phase 2	NCT05943223 Comparator	Sep 2024 → Jul 2025	appendicitis	McMaster Children's Hospital	Completed	No outcome recorded
Phase 2	NCT05121974 Comparator	Aug 2022 → Mar 2025 overdue	shigellosis	International Centre for Diarrhoeal Disease Research, Bangladesh	Active not recruiting	No outcome recorded
Phase 2	NCT05294588 Background	Apr 2022 → Feb 2026	gonorrhea	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT05398081 Comparator	Dec 2021 → Feb 2022	—	Dr. Promise Tamunoipiriala Jaja	Completed	No outcome recorded
Phase 2	NCT02742948 Comparator	Apr → Aug 2016	endometritis	Cairo University	Unknown	No outcome recorded
Phase 2	NCT02257918 Comparator	Nov 2014 → Dec 2015	gonorrhea	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded
Phase 2	NCT02098486 Comparator	Mar 2014 → Sep 2015	cholangitis	Kangbuk Samsung Hospital	Completed	No outcome recorded
Phase 2	NCT01756924 Comparator	Dec 2012 → Jul 2014	periprosthetic joint infection	Arrevus Inc.	Terminated	No outcome recorded
Phase 2	NCT01757236 Background	Oct 2012 → Apr 2016	periprosthetic joint infection	University Hospital, Tours	Unknown	No outcome recorded
Phase 2	NCT01160640 Comparator	Nov 2010 → Aug 2015	pelvic inflammatory disease	Harold Wiesenfeld	Completed	No outcome recorded
Phase 2	NCT00797108 Comparator	Jan → Jun 2009	bacterial pneumonia	Pfizer	Completed	No outcome recorded
Phase 2	NCT00111644 Comparator	Mar 2005 → Jan 2007	bacterial pneumonia	Hoffmann-La Roche	Completed	No outcome recorded

Phase 2/35 trials
Phase 2/3	NCT07229755 Background	Jul → Dec 2024	urinary tract infection	Ain Shams University	Completed	No outcome recorded
Phase 2/3	NCT05293132 Background	Feb 2022 → Jun 2023	infectious disease with sepsis	Ain Shams University	Completed	No outcome recorded
Phase 2/3	NCT04879030 Background	Jan → Aug 2020	chronic obstructive pulmonary disease	Haiphong University of Medicine and Pharmacy	Completed	No outcome recorded
Phase 2/3	NCT02605122 Comparator	Apr 2016 → Mar 2018	bacterial pneumonia	Melinta Therapeutics, Inc.	Terminated	No outcome recorded
Phase 2/3	NCT01530763 Comparator	Sep 2012 → Apr 2014	infectious disease	Forest Laboratories	Completed	No outcome recorded
Phase 331 trials
Phase 3	NCT07332325 Background	Oct 2026 → Mar 2029 expected	infectious disease with sepsis, tuberculosis	University of Virginia	Not yet recruiting	No outcome recorded
Phase 3	NCT07631364 Comparator	Sep 2026 → Oct 2028 expected	gonorrhea	Assistance Publique - Hôpitaux de Paris	Not yet recruiting	No outcome recorded
Phase 3	NCT06819592 Comparator	Oct 2025 → Aug 2029 expected	brain injury, intellectual disability	The George Institute	Recruiting	No outcome recorded
Phase 3	NCT06847126 Comparator	Feb 2025 → Jun 2026 overdue	liver abscess (disease)	Post Graduate Institute of Medical Education and Research, Chandigarh	Recruiting	No outcome recorded
Phase 3	NCT05971550 Comparator	Sep 2023 → Dec 2025	gonorrhea	Assistance Publique - Hôpitaux de Paris	Unknown	No outcome recorded
Phase 3	NCT05074147 Background	May 2022 → Nov 2024	osteomyelitis	Tourcoing Hospital	Withdrawn	No outcome recorded
Phase 3	NCT05417997 Background	May → Dec 2021	COVID-19, bacterial pneumonia, influenza	RAAS Nutritionals, LLC	Completed	No outcome recorded
Phase 3	NCT03959527 Comparator	Nov 2019 → Aug 2023	gonorrhea	Global Antibiotics Research and Development Partnership	Completed	No outcome recorded
Phase 3	NCT04010539 Comparator	Oct 2019 → Oct 2023	gonorrhea	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT03688295 Comparator	Feb 2019 → Sep 2025 overdue	appendicitis	Centre Hospitalier Universitaire, Amiens	Recruiting	No outcome recorded
Phase 3	NCT03439124 Comparator	Nov 2017 → Mar 2020	bacterial pneumonia	Basilea Pharmaceutica	Completed	No outcome recorded
Phase 3	NCT03294395 Comparator	Sep 2017 → Jun 2020	gonorrhea	Public Health Service of Amsterdam	Completed	No outcome recorded
Phase 3	NCT02473263 Comparator	May 2016 → Feb 2019	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02659033 Comparator	Mar 2016	—	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02424461 Comparator	Jan 2015 → Feb 2019	urinary tract infection	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 3	NCT02443285 Comparator	Jan 2015 → Dec 2019	infectious peritonitis	Tanta University	Unknown	No outcome recorded
Phase 3	NCT02210325 Comparator	Aug 2014 → Feb 2017	gonorrhea	Melinta Therapeutics, Inc.	Completed	No outcome recorded
Phase 3	NCT02015637 Comparator	Jan → Nov 2014	gonorrhea	Melinta Therapeutics, Inc.	Terminated	No outcome recorded
Phase 3	NCT01371838 Comparator	Dec 2011 → May 2013	bacterial pneumonia	Pfizer	Completed	No outcome recorded
Phase 3	NCT01602874 Comparator	Jan 2011 → May 2014	bacterial pneumonia	Pfizer	Withdrawn	No outcome recorded
Phase 3	NCT00914888 Comparator	Jan 2011 → May 2014	bacterial pneumonia	Wyeth is now a wholly owned subsidiary of Pfizer	Withdrawn	No outcome recorded
Phase 3	NCT01254344 Comparator	Dec 2010 → Dec 2011	infectious disease	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT01014013 Comparator	Apr 2008 → Feb 2009	urinary tract infection	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00717561 Comparator	Feb 2008 → May 2009	pneumonia	Bayer	Completed	No outcome recorded
Phase 3	NCT00621504 Comparator	Jan → Dec 2008	bacterial pneumonia	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT00509106 Comparator	Jul 2007 → Aug 2008	bacterial pneumonia	Forest Laboratories	Completed	No outcome recorded
Phase 3	NCT00349622 Comparator	Jul 2006 → Nov 2012	amyotrophic lateral sclerosis	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT00326287 Comparator	Jun 2006 → Jul 2007	pneumonia	Basilea Pharmaceutica	Completed	No outcome recorded
Phase 3	NCT00769171 Comparator	Oct 2005 → Dec 2006	infectious peritonitis	Bayer	Completed	No outcome recorded
Phase 3	NCT00138801 Comparator	Mar 2004 → Mar 2008	Lyme disease	Sorlandet Hospital HF	Completed	No outcome recorded
Phase 3	NCT00431678 Comparator	Jan 2004 → Jul 2005	pneumonia	Bayer	Completed	No outcome recorded

Phase 428 trials
Phase 4	NCT07537413 Comparator	Sep 2026 → Aug 2027 expected	pneumonia	University of Maryland, Baltimore	Not yet recruiting	No outcome recorded
Phase 4	NCT07236944 Comparator	Dec 2025 → Mar 2029 expected	bacterial urinary tract infection	Uppsala University	Recruiting	No outcome recorded
Phase 4	NCT05544565 Background	Mar 2023 → Jan 2028 expected	acute pyelonephritis	Assistance Publique - Hôpitaux de Paris	Recruiting	No outcome recorded
Phase 4	NCT05980871 Comparator	Mar 2023 → Jul 2025	syphilis	National Taiwan University Hospital	Terminated	No outcome recorded
Phase 4	NCT05199324 Comparator	Jun 2022 → May 2026 overdue	gram-negative bacterial infections	Tan Tock Seng Hospital	Recruiting	No outcome recorded
Phase 4	NCT05027516 Comparator	Jan → May 2022	gonorrhea	Institute of Tropical Medicine, Belgium	Completed	No outcome recorded
Phase 4	NCT06090565 Comparator	Apr 2021 → Jun 2022	gonorrhea	Bulovka Hospital	Completed	No outcome recorded
Phase 4	NCT04563325 Comparator	Sep 2020 → Jan 2024	bacterial infectious disease, infective arthritis, osteomyelitis	Rigshospitalet, Denmark	Completed	No outcome recorded
Phase 4	NCT03068741 Comparator	Mar 2020 → Nov 2025	infectious disease with sepsis	Dr. Damon Scales	Completed	No outcome recorded
Phase 4	NCT04141787 Comparator	Jul 2019 → Jul 2023	abscess, bacterial arthritis, infectious disorder of the nervous system, osteomyelitis +1	Vancouver Island Health Authority	Unknown	No outcome recorded
Phase 4	NCT03560232 Comparator	Jul 2018 → Feb 2020	—	Mercy Health Ohio	Terminated	No outcome recorded
Phase 4	NCT03922919 Comparator	Apr 2018 → Apr 2020	bacterial infectious disease	Centre Hospitalier Universitaire de Besancon	Unknown	No outcome recorded
Phase 4	NCT03087656 Comparator	Mar 2017 → Feb 2024	cholangitis	University of Southern California	Unknown	No outcome recorded
Phase 4	NCT02384200 Background	Mar 2015 → Feb 2017	nephrolithiasis, urinary tract infection	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT01723150 Comparator	Nov 2013 → Jan 2018	liver abscess (disease)	National University Hospital, Singapore	Completed	No outcome recorded
Phase 4	NCT01669980 Comparator	Oct 2012 → May 2014	pneumonia	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT01645735 Comparator	Oct 2012 → Dec 2013	respiratory tract infectious disorder	Forest Laboratories	Completed	No outcome recorded
Phase 4	NCT01659866 Comparator	Aug 2012 → Aug 2015	infectious disease	Northwestern University	Completed	No outcome recorded
Phase 4	NCT01635530 Comparator	Aug 2012 → Dec 2017	Lyme disease	Turku University Hospital	Completed	No outcome recorded
Phase 4	NCT01421693 Comparator	Sep 2011 → Jul 2014	typhoid fever	Oxford University Clinical Research Unit, Vietnam	Completed	No outcome recorded
Phase 4	NCT01207739 Comparator	Sep 2010 → Oct 2013	Borrelia infectious disease, Lyme disease	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT00895089 Comparator	May 2009 → Dec 2010	liver abscess (disease)	Kaohsiung Veterans General Hospital.	Completed	No outcome recorded
Phase 4	NCT02123628 Comparator	Jun 2007 → Jun 2010	diabetes mellitus	Tourcoing Hospital	Completed	No outcome recorded
Phase 4	NCT00230971 Comparator	Oct 2005 → Sep 2008	abscess, appendicitis, cholecystitis, diverticulitis +2	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00195351 Comparator	Sep 2005 → Feb 2008	appendicitis, cholecystitis, diverticulitis, nosocomial infection +1	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT00136656 Comparator	Jul 2005 → Jun 2008	pyelonephritis	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT01166932 Comparator	Apr 2005 → Apr 2007	pneumonia	UPECLIN HC FM Botucatu Unesp	Completed	No outcome recorded
Phase 4	NCT00358202 Comparator	Mar 2002 → Apr 2006	pneumonia	CPL Associates	Completed	No outcome recorded

Phase not applicable18 trials
—	NCT07552870 Comparator	Jan → Apr 2026	cirrhosis of liver	Shahida Islam Medical Complex	Completed	No outcome recorded
—	NCT07148622 Comparator	Oct 2024 → Aug 2025	preterm premature rupture of the membranes	Yuzuncu Yil University	Completed	No outcome recorded
—	NCT06437964 Comparator	May 2024 → Jan 2026	cirrhosis of liver, esophageal varices with bleeding, portal hypertension	Second Affiliated Hospital, School of Medicine, Zhejiang University	Completed	No outcome recorded
—	NCT06080698 Comparator	Feb 2024 → May 2027 expected	gram-negative bacterial infections	Johns Hopkins University	Recruiting	No outcome recorded
—	NCT06166381 Background	Jan → Dec 2024 overdue	bacterial infectious disease	University of Duhok	Recruiting	No outcome recorded
—	NCT06454643 Comparator	Jan 2020 → Jan 2021	—	Al-Rasheed University College	Completed	No outcome recorded
—	NCT03657836 Background	Aug 2018 → Jan 2019	bronchitis	Nazarbayev University Medical Center	Completed	No outcome recorded
—	NCT02800785 Comparator	May 2016 → Mar 2020	appendicitis	University of Washington	Completed	No outcome recorded
—	NCT02567825 Background	Nov 2015 → Mar 2020	otitis media	Alejandro Hoberman	Completed	No outcome recorded
—	NCT02515565 Background	Sep 2015 → Apr 2018	pneumonia	University of Granada	Unknown	No outcome recorded
—	NCT03449940 Comparator	Jan 2015 → Jan 2017	erectile dysfunction	Ministry of Health, Jamaica	Completed	No outcome recorded
—	NCT03061604 Background	Nov 2014 → Nov 2017	varicose disease	Theodor Bilharz Research Institute	Completed	No outcome recorded
—	NCT01163994 Comparator	Jun 2010 → Oct 2017	—	University Medical Centre Ljubljana	Unknown	No outcome recorded
—	NCT00942006 Comparator	Jul 2009 → Nov 2010	—	University Medical Centre Ljubljana	Unknown	No outcome recorded
—	NCT00910533 Comparator	Jan 2009 → Dec 2018	Lyme disease	University Medical Centre Ljubljana	Unknown	No outcome recorded
—	NCT00566111 Comparator	Sep 2007 → Dec 2009	bipolar depression	Yale University	Terminated	No outcome recorded
—	NCT00644150 Background	Apr 2007 → Jul 2011	HIV infectious disease, chlamydia infectious disease, gonorrhea	University of California, Los Angeles	Completed	No outcome recorded
—	NCT00462020 Comparator	Mar 2007 → Nov 2008	appendicitis	Children's Mercy Hospital Kansas City	Completed	No outcome recorded

Evidence & citations 27 cited values

Every value below carries the sentence it was read from. 197 sources stand behind the page.

Field	Value	Cited text
Known as	ceftriaxone	“Patients not already receiving a therapeutic antibiotic will be prescribed cefotaxime 1g six-hourly or ceftriaxone 1g daily, with dose adjusted as appropriate for organ...” NCT02389036 ↗ 182 “Beta lactam antibiotics for non-ESBL E. coli infections include preferred ceftriaxone or alternative cephalosporins (cefepime, ceftazidime), penicillins...” NCT07318584 ↗ “Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until...” NCT02515565 ↗ “The intravenous-group will receive Beta-lactam antimicrobials (i.e Piperacillin-Tazobactum 4.5g q 8 hourly or Ceftriaxone 1g q 12 hourly or Meropenem 1g q 8 hourly or...” NCT06847126 ↗ “empiric initiation of the enhanced spectrum antimicrobial therapy regimen (rifampin, isoniazid, linezolid, and levofloxacin) for 14 days plus standard care which includes...” NCT07332325 ↗ “The beta-lactam antibiotics with activity against gram-negative bacilli in this study included piperacillin-tazobactam, ticarcillin-clavulanate, imipenem-cilastin, meropenem,...” NCT04879030 ↗ “Ceftriaxone infusion. Ceftriaxone is a beta-lactam antibiotic that is the standard-of-care antibiotic for prophylaxis of asymptomatic bacteriuria in Switzerland.” NCT05761405 ↗ “Commonly used intravenous antibiotics (and doses) for treatment of Gram-negative bacteraemia include ceftriaxone 2 g daily or cefazolin 2 g three times daily.” NCT05199324 ↗ “Ceftriaxone (50 mg/kg once a day by intravenous/intramuscular route) AND/OR Amikacin (20 mg/kg once a day by intravenous/intramuscular route) during 3 days.” NCT05544565 ↗ “standard to double dosing of beta-lactam antibiotics (cefuroxime, ceftazidime, ceftriaxone, cefotaxime, amoxicillin, amoxicillin/clavulanic acid,” PMID 40119275 ↗ Mar 2025 “Parenteral antibiotic (ceftriaxone) 1 g to be given in 3 doses, at induction of anesthesia, 12 hours postoperative, and 24 hours postoperative.” NCT06166381 ↗ “Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.” NCT02736682 ↗ “These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid.” NCT02605122 ↗ “Patients will be given standard therapy antibiotics cefuroxime and ceftriaxone for up to 7 days period.” NCT03657836 ↗ “to receive intravenous ceftriaxone 2 g or placebo once within the 12 h following tracheal intubation.” PMID 38262428 ↗ Jan 2024 “Intravenous ceftriaxone with either oral methyl prednisolone or intravenous dexamethasone was given” NCT04935515 ↗ “Drugs used would be anything from: zosyn, ciprofloxacin or ceftriaxone and flagyl, augmentin” NCT05724628 ↗ “Includes antibiotics such as ceftriaxone, cefepime, piperacillin-tazobactam, and meropenem.” NCT06080698 ↗ “Single dose of Rocephine® (= ceftriaxone 1g + lidocaine 35mg) intramuscular injection” NCT05027516 ↗ “Ceftriaxone was used as standard-of-care cephalosporin for the treatment of CAP.” NCT03439124 ↗ “Ceftriaxone 2 gr and Metronidazole 1.5 gr per day for 2 days postoperatively” NCT04977882 ↗ “After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter” NCT01207739 ↗ “a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day)” NCT05821478 ↗ “or intravenous ceftriaxone for 4 days followed by oral cefixime for 6 days” PMID 22291112 ↗ Jan 2012 “cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside” NCT01602874 ↗ “2 g ceftriaxone by intravenous injection every 24 h up to the operation” PMID 32487213 ↗ Jun 2020 “Ceftriaxone 1gm intravenously dose of ceftriaxone 1gm at 24 h interval” NCT04056806 ↗ “ceftriaxone 2gm/24 hour or meropenem 1g/8 hours, linezolid 600/12hours” NCT05293132 ↗ “Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004” NCT02419001 ↗ “cephalosporins; cefotaxime, cefuroxime, ceftriaxone, 3) carbapenems” NCT07236944 ↗ “Intravenous infusion of 2.0g ceftriaxone before endoscopic therapy” NCT06437964 ↗ “* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily” NCT02123628 ↗ “Ampicillin 12g/24h plus ceftriaxone 4g/12h continuous infusion.” NCT06423898 ↗ “Cephalosporin- Ceftriaxone, (Ceftrisol Plus, Rocephin)” NCT05849090 ↗ “Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h” NCT02795949 ↗ “ceftriaxone and azithromycin capsules” NCT04461925 ↗ “Ceftriaxone 2 gm IV q12h for 3 days” NCT04999592 ↗ “IV ceftriaxone 2g or ampiclox 2g” NCT03518463 ↗ “Ceftriaxone : 1g/day parenteral” NCT06572761 ↗ “IV Ceftriaxone (Cephalosporin)” NCT05121974 ↗ “Ceftriaxone : 1g/j, 7j” NCT07030673 ↗ “Drug: Ceftriaxone” NCT01160640 ↗ “Ceftriaxone*” NCT02099240 ↗ “ceftriaxone” NCT05750966 ↗ NCT01659866 ↗ NCT00895089 ↗ NCT00481702 ↗ NCT05156437 ↗ NCT02015637 ↗ NCT05971550 ↗ NCT03449940 ↗ NCT03681431 ↗ NCT04870138 ↗ NCT00449800 ↗ NCT03179384 ↗ NCT01635530 ↗ NCT00037479 ↗ NCT02735707 ↗ NCT03061604 ↗ NCT00326287 ↗ NCT01530763 ↗ NCT00942006 ↗ NCT06785402 ↗ NCT00374959 ↗ NCT07552870 ↗ NCT03959527 ↗ NCT00797108 ↗ NCT04839653 ↗ NCT02177994 ↗ NCT00451386 ↗ NCT00431678 ↗ NCT00111644 ↗ NCT03294395 ↗ NCT01745679 ↗ NCT01163994 ↗ NCT03922919 ↗ NCT01669980 ↗ NCT07229755 ↗ NCT03560232 ↗ NCT04202068 ↗ NCT02210325 ↗ NCT01254344 ↗ NCT02257918 ↗ NCT00429975 ↗ NCT06532409 ↗ NCT02334124 ↗ NCT01278017 ↗ NCT01645735 ↗ NCT03895567 ↗ NCT00509106 ↗ NCT00035347 ↗ NCT00157898 ↗ NCT01014013 ↗ NCT07484633 ↗ NCT07710118 ↗ NCT01390623 ↗ NCT01265173 ↗ NCT01988428 ↗ NCT03840811 ↗ NCT01559753 ↗ NCT02424461 ↗ NCT01757236 ↗ NCT05417997 ↗ NCT02742948 ↗ NCT01421693 ↗ NCT00769171 ↗ NCT01166932 ↗ NCT04975945 ↗ NCT01473836 ↗ NCT00512616 ↗ NCT03477422 ↗ NCT04041791 ↗ NCT01371838 ↗ NCT06406114 ↗ NCT03068741 ↗ NCT00195351 ↗ NCT00914888 ↗ NCT06616168 ↗ NCT05216744 ↗ NCT06494072 ↗ NCT00161330 ↗ NCT01247909 ↗ NCT05051163 ↗ NCT00717561 ↗ NCT03174236 ↗ NCT05294588 ↗ NCT00566111 ↗ NCT05079620 ↗ NCT01723150 ↗ NCT02800785 ↗ NCT07308457 ↗ NCT02224040 ↗ NCT02443285 ↗ NCT02473640 ↗ NCT05375240 ↗ NCT04010539 ↗ NCT02142751 ↗ NCT01678365 ↗ NCT04218695 ↗ NCT06349122 ↗ NCT04066621 ↗ NCT06819592 ↗ NCT02098486 ↗ NCT05470517 ↗ NCT02473263 ↗ NCT07631364 ↗ NCT05149287 ↗ NCT00349622 ↗ NCT00358202 ↗ NCT03012360 ↗ NCT00493220 ↗ NCT02746276 ↗ NCT00002052 ↗ NCT07485010 ↗ NCT02384200 ↗ NCT05398081 ↗ NCT03087656 ↗ NCT06454643 ↗ NCT05943223 ↗ NCT00591318 ↗ NCT05980871 ↗ NCT04141787 ↗ NCT00189384 ↗ NCT01756924 ↗ NCT00004216 ↗ NCT00230971 ↗ NCT02561442 ↗ NCT07148622 ↗ NCT06396078 ↗ NCT00621504 ↗ NCT00462020 ↗ NCT06611111 ↗ NCT02567825 ↗ NCT00138801 ↗ NCT07537413 ↗ NCT06527989 ↗ NCT02996656 ↗ NCT00372541 ↗ NCT02659033 ↗ NCT00000648 ↗ NCT03413384 ↗ NCT03794765 ↗ NCT00910533 ↗
Known as	Anerning particle	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03675178 ↗
Known as	Cefraden	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxon	“* Ceftriaxon : 1g to 2g/day in IV, IM or SC” NCT05074147 ↗ 2 NCT06090565 ↗ NCT04563325 ↗
Known as	Ceftriaxona	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone (as sodium)	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone disodium salt	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone disodium salt hemiheptahydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone sodium	“Anerning particle ,1 bag/time,3 times/ day, +ceftriaxone sodium,50mg/kg/time, 1 time/day, the total amount per day does not exceed 2g，for 10 days.When the condition is cured,...” NCT03675178 ↗ 10 “Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is...” NCT01473836 ↗ “Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously.” NCT00230971 ↗ “Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously.” NCT00195351 ↗ “Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection.” NCT00644150 ↗ “Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).” NCT03895567 ↗ “Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days” NCT00451386 ↗ “Ceftriaxone sodium and Sulbactam Sodium for injection” NCT04202068 ↗ “Drug: Ceftriaxone Sodium” NCT05051163 ↗ NCT06220929 ↗ NCT05654896 ↗
Known as	Ceftriaxone sodium anhydrous	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone sodium component of rocephin kit	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone sodium hydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftriaxone sodium sesquaterhydrate	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Ceftrisol Plus	“Cephalosporin- Ceftriaxone, (Ceftrisol Plus, Rocephin)” NCT05849090 ↗
Known as	CRO	“a single 1 g intravenous (IV) dose of ceftriaxone (CRO) plus doxycycline (DOX) versus a single 800 mg oral dose of cefixime (CFM) plus DOX for the treatment of NG-CT co-infection” PMID 35810277 ↗ Jul 2022
Known as	CTRX	“intravenous MNZ combined with ceftriaxone (CTRX) in Japanese subjects” PMID 25442806 ↗ Nov 2014
Known as	CTX	“In this pilot study, we aimed to assess the feasibility of a randomized study of whether prophylactic ceftriaxone (CTX), administered to hospitalized patients with advanced...” PMID 38180983 ↗ Jan 2024 2 “ceftriaxone (CTX): 50 mg/kg q12h (max. 4 g per day)” NCT07484633 ↗ “ceftriaxone-metronidazole (CTX/MET)” PMID 22439781 ↗ Mar 2012
Known as	Megion	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	RO 13-9904	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	RO-13-9904/001	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Rocefin	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Known as	Rocephin	“The treatment involves 10 weeks of either intravenous antibiotic called ceftriaxone (also known as Rocephin) or intravenous placebo (inactive substance).” NCT00037479 ↗ 6 “Here, Ceftriaxone (Rocephin®) a third generation cephalosporin will be used” NCT05398081 ↗ “a 3-week course of ceftriaxone (Rocephin) IV injection (daily dose 2g/day)” NCT05821478 ↗ “Intravenous injection of 500mg of ceftriaxone sodium (Rocephin®; Roche).” NCT03895567 ↗ “Cephalosporin- Ceftriaxone, (Ceftrisol Plus, Rocephin)” NCT05849090 ↗ “Ceftriaxone (Rocephin®)” NCT06611111 ↗ “Ceftriaxone (Rocephin®)” NCT07229755 ↗
Known as	Rocephin (ceftriaxone)	“Rocephin (ceftriaxone)” NCT04999592 ↗
Known as	Sodium ceftriaxone, anhydrous	ChEMBL registry synonym — accepted as the source's own label CHEMBL161 ↗
Action	Activate	“ceftriaxone increases EAAT2 activity” PMID 25297012 ↗ Oct 2014
Modality	Other / unclassified	“cephalosporine : ceftriaxone by intra venous route” NCT00136656 ↗
Route	Intravenous	“Ceftriaxone IV on day 1” NCT00004216 ↗